MSD Deutschland in the news

A new digital guide, MySunrise, supports bladder cancer patients in Germany with information on diagnosis, treatment, and aftercare, developed with MSD Sharp & Dohme GmbH.

MySunrise is a new digital platform providing comprehensive information and support for bladder cancer patients in Germany, developed with MSD Sharp & Dohme GmbH's assistance.

MSD Deutschland supported the development of MySunrise, a new digital platform offering comprehensive information and support for bladder cancer patients in Germany.

A health report commissioned by MSD reveals that elevated LDL-cholesterol costs the German economy 17.3 billion Euros annually, highlighting the significant economic burden of cardiovascular diseases.

A new health report highlights that high LDL cholesterol levels cost the German economy 17.3 billion euros annually through medical expenses and lost productivity.

High LDL cholesterol levels generate 17.3 billion euros in annual costs for the German economy due to healthcare spending and lost productivity.

High LDL cholesterol levels cost the German economy 17.3 billion euros in 2024 through medical expenses and lost productivity.

AstraZeneca and MSD Deutschland are collaborating on a major awareness campaign to increase prostate cancer screening rates and reduce social stigma around the disease.

MSD Deutschland and AstraZeneca are partnering on a nationwide awareness campaign to increase prostate cancer screening rates and reduce social stigma.

Analysis highlights MSD and other Dow Jones blue chips as reliable dividend-growth investments for long-term retirement portfolios due to strong earnings and manageable payout ratios.

MSD has launched Enflonsia, a weight-independent single-dose antibody treatment to protect infants from respiratory syncytial virus throughout their first season.

MSD is protesting German healthcare spending cuts by canceling a high-profile expansion ceremony in Bavaria while continuing project construction.

Partnerships with AstraZeneca to launch a nationwide ovarian cancer awareness campaign in Germany to address critical information gaps among women.

Keytruda, a cancer drug by MSD, is facing scrutiny over its high price in Germany, with calculations suggesting it is vastly overpriced compared to its fair value.

Research highlights immense profits from MSD's drug Keytruda, raising concerns about its high price and the impact on patients and healthcare systems.

Keytruda, the top-selling cancer drug, is reportedly overpriced according to calculations by an international health insurance association.

Keytruda, an effective but expensive cancer drug developed by MSD, has significantly improved survival rates for various cancers, but its high cost is raising concerns about healthcare system sustainability and affordability.

Merck & Co., Inc. (MSD outside the USA) stock offers stability in the volatile pharma market due to its focus on innovative therapies in oncology, vaccines, and diabetes, attracting investors in German-speaking markets.

MSD Deutschland's Country Medical Director discusses the potential of the electronic health record (ePA) for research, emphasizing structured data, interoperability, and the electronic vaccination pass as a key use case.

MSD is relocating its Lucerne headquarters to a new building near the train station, offering enhanced amenities for its 750 employees.